However, we have recently reported how the basal number of RAD51 foci number in proliferating (geminin positive) tumor cells (RAD51 foci score), detected in formalin-fixed paraffin-embedded (FFPE) tumor samples using an immunofluorescence assay, correlated with tumor HR deficiency status and was predictive of olaparib response in an ovarian xenobank; RAD51 foci score also predicted the response to platinum-based therapy in breast cancer [22,23]. The gene discussed is RAD51; the disease is neoplasm.